Citadel Advisors
ONCT

Citadel Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Citadel Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,714
Closed -$29.1K – 15857
2023
Q4 		$29.1K Buy
+2,714
New +$19.5K ﹤0.01% 12292
2023
Q2 		– Sell
-196
Closed -$1.29K – 15544
2023
Q1 		$3.07K Sell
196
-80
-29% -$1.57K ﹤0.01% 14074
2022
Q4 		$5.51K Buy
+276
New +$5.49K ﹤0.01% 13987
2022
Q3 		– Sell
-58,148
Closed -$1.25M – 13914
2022
Q2 		$1.29M Buy
58,148
+48,893
+528% +$1.09M ﹤0.01% 6443
2022
Q1 		$257K Buy
9,255
+5,031
+119% +$183K ﹤0.01% 10944
2021
Q4 		$192K Buy
4,224
+21
+0.5% +$1.41K ﹤0.01% 11904
2021
Q3 		$350K Buy
4,203
+782
+23% +$64.7K ﹤0.01% 10720
2021
Q2 		$325K Sell
3,421
-3,808
-53% -$452K ﹤0.01% 11076
2021
Q1 		$1.2M Buy
+7,229
New +$956K ﹤0.01% 7645
2018
Q3 		– Sell
-138
Closed -$296K – 9829
2018
Q2 		$296K Buy
+138
New +$350K ﹤0.01% 7232
2016
Q4 		– Sell
-39
Closed -$43K – 8002
2016
Q3 		$43K Buy
+39
New +$34K ﹤0.01% 6879
2016
Q2 		– Sell
-15
Closed -$11K – 7556
2016
Q1 		$11K Buy
+15
New +$13K ﹤0.01% 6592
2015
Q4 		– Sell
-10
Closed -$10K – 9331
2015
Q3 		$10K Sell
10
-11
-52% -$16.1K ﹤0.01% 8476
2015
Q2 		$44K Buy
21
+1
+5% +$1.42K ﹤0.01% 7745
2015
Q1 		$19K Buy
20
+9
+82% +$8.95K ﹤0.01% 7949
2014
Q4 		$11K Sell
11
-8
-42% -$7.14K ﹤0.01% 8111
2014
Q3 		$19K Buy
19
+4
+27% +$5.9K ﹤0.01% 7493
2014
Q2 		$29K Buy
15
+9
+150% +$17.8K ﹤0.01% 7098
2014
Q1 		$13K Buy
+6
New +$14.9K ﹤0.01% 7433
2013
Q4 		– Sell
-6
Closed -$13.7K – 7208
2013
Q3 		$17K Sell
6
-25
-81% -$124K ﹤0.01% 6308
2013
Q2 		$284K Buy
+31
New +$239K ﹤0.01% 4355

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's ONCT Position: Q1 2024 in Review

Citadel Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 2,714 shares — an estimated $29.1K sold.

Citadel Advisors first reported a position in ONCT in Q2 2013 and held it in 21 quarters. The position peaked at $1.29M in Q2 2022. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

  • Citadel Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 2,714 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $29.1K.
  • Citadel Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 21 quarters.
  • Citadel Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.29M in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.